CHROMADEX CORP (CDXC) Stock Price, Quote, News and Overview
NASDAQ:CDXC - Nasdaq - US1710774076 - Common Stock - Currency: USD
CDXC Quote, Performance and Key Statistics
7.87
-0.07 (-0.88%)
The current stock price of CDXC is 7.87 USD. In the past month the price increased by 33.16%. In the past year, price increased by 121.07%.
CDXC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.37 | 160.15B | ||
| DHR | DANAHER CORP | 26.46 | 141.04B | ||
| A | AGILENT TECHNOLOGIES INC | 20.02 | 30.30B | ||
| IQV | IQVIA HOLDINGS INC | 13.49 | 26.50B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 25.8 | 22.13B | ||
| WAT | WATERS CORP | 28.47 | 20.10B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 32.31 | 15.51B | ||
| ILMN | ILLUMINA INC | 31.57 | 12.24B | ||
| ICLR | ICON PLC | 10.35 | 11.97B | ||
| RVTY | REVVITY INC | 19.24 | 11.33B | ||
| TEM | TEMPUS AI INC | N/A | 9.15B | ||
| QGEN | QIAGEN N.V. | 19.04 | 9.09B |
Related stock screener links
About CDXC
Company Profile
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. The firm is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Company Info
CHROMADEX CORP
10900 Wilshire Blvd, Suite 600
Los Angeles CALIFORNIA 90024 US
CEO: Robert Fried
Employees: 106
Company Website: https://chromadex.com/default.aspx
Investor Relations: https://investors.chromadex.com/
Phone: 13103886706
CHROMADEX CORP / CDXC FAQ
What is the stock price of CHROMADEX CORP today?
The current stock price of CDXC is 7.87 USD. The price decreased by -0.88% in the last trading session.
What is the ticker symbol for CHROMADEX CORP stock?
The exchange symbol of CHROMADEX CORP is CDXC and it is listed on the Nasdaq exchange.
On which exchange is CDXC stock listed?
CDXC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CHROMADEX CORP stock?
9 analysts have analysed CDXC and the average price target is 9.21 USD. This implies a price increase of 16.97% is expected in the next year compared to the current price of 7.87. Check the CHROMADEX CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CHROMADEX CORP worth?
CHROMADEX CORP (CDXC) has a market capitalization of 611.89M USD. This makes CDXC a Small Cap stock.
How many employees does CHROMADEX CORP have?
CHROMADEX CORP (CDXC) currently has 106 employees.
What are the support and resistance levels for CHROMADEX CORP (CDXC) stock?
CHROMADEX CORP (CDXC) has a support level at 7.71 and a resistance level at 7.88. Check the full technical report for a detailed analysis of CDXC support and resistance levels.
Is CHROMADEX CORP (CDXC) expected to grow?
The Revenue of CHROMADEX CORP (CDXC) is expected to grow by 20.72% in the next year. Check the estimates tab for more information on the CDXC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CHROMADEX CORP (CDXC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CDXC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CDXC, evaluating the profitability, health, valuation and growth aspects
- CHROMADEX CORP (CDXC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CHROMADEX CORP (CDXC) Sales and EPS estimates to see what analysts future expectations are.
- CHROMADEX CORP (CDXC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CHROMADEX CORP (CDXC) Insider and Institutional Ownership to learn about the owners and their transactions.
- CHROMADEX CORP (CDXC) Stock Chart to make your own analysis
- CHROMADEX CORP (CDXC) Latest news and press-releases to stay up to date.
Does CHROMADEX CORP (CDXC) stock pay dividends?
CDXC does not pay a dividend.
When does CHROMADEX CORP (CDXC) report earnings?
CHROMADEX CORP (CDXC) will report earnings on 2025-05-06, after the market close.
What is the Price/Earnings (PE) ratio of CHROMADEX CORP (CDXC)?
The PE ratio for CHROMADEX CORP (CDXC) is 78.7. This is based on the reported non-GAAP earnings per share of 0.1 and the current share price of 7.87 USD. Check the full fundamental report for a full analysis of the valuation metrics for CDXC.
CDXC Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CDXC. When comparing the yearly performance of all stocks, CDXC is one of the better performing stocks in the market, outperforming 98.21% of all stocks.
CDXC Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CDXC. While CDXC has a great health rating, its profitability is only average at the moment.
CDXC Financial Highlights
Over the last trailing twelve months CDXC reported a non-GAAP Earnings per Share(EPS) of 0.1. The EPS increased by 242.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.58% | ||
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| Debt/Equity | 0 |
CDXC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to CDXC. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 19% and a revenue growth 20.72% for CDXC